Dihydroergocornine

Identification

Summary

Dihydroergocornine is a nootropic with an unknown mechanism of action indicated in individuals over sixty who manifest signs and symptoms of an idiopathic decline in mental capacity.

Generic Name
Dihydroergocornine
DrugBank Accession Number
DB11273
Background

Dihydroergocornine is one of the dihydrogenated ergot compounds that present very large hypotensive effects.1 It is an artificial derivative of the crude extract of ergot and later purified, ergocornine.2 The formation of dihydroergocornine implies the hydrogenation of the double bonds in the lysergic acid.3 Dihydroergocornine presents a formula of 9,10 alpha-dihydro-12'-hydroxy-2',5'alpha-bis(1-methylethyl)-ergotaman-3',6',18-trione.7 It is found as one of the components in the ergoloid mesylate mixture. To know more about this mixture please refer to Ergoloid mesylate

Type
Small Molecule
Groups
Approved
Structure
Weight
Average: 563.699
Monoisotopic: 563.31076944
Chemical Formula
C31H41N5O5
Synonyms
  • 9,10-dihydroergocornine
  • Dihydroergocornine

Pharmacology

Indication

To know more about the approved indications please visit Ergoloid mesylate

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Used in combination for symptomatic treatment ofNo primary neurologial disease, idiopathic decreased mental activityCombination Product in combination with: Dihydroergocristine (DB13345), Dihydro-alpha-ergocryptine (DB11274)••••••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

It is reported that dihydroergocornine administration, in non-toxic doses, presents sympatholytic and hypotensive properties which are observed as a significantly decreased mean arterial pressure.2 In the brain, the activity of dihydroergocornine was observed as a decrease in cerebral blood flow, cerebral vascular resistance and oxygen uptake. The effect in the brain seems to allow a cerebral metabolic homeostasis.1 To know more about the pharmacology please visit Ergoloid mesylate

Mechanism of action

The mechanism of action by which dihydroergocornine exerts its effects are not entirely defined. However, it is reported that dihydroergocornine has central and peripheral effects. The fall in blood pressure seems to be related to the stimulation of the vasodilator center.4 It has been demonstrated that dihydroergocornine possesses potent adrenolytic and sympathicolytic actions.5 The effect of dihydroergocornine is related to the inhibitory effect against the serotonin and noradrenaline receptors in which dihydroergocornine seems to be very potent against a stimulation-induced noradrenaline overflow. It also presents a stimulatory effect in arterial and venous smooth muscle when administered at slightly higher concentrations than the necessary for the inhibitory effect.6

TargetActionsOrganism
ASerotonin Receptors
antagonist
agonist
Humans
ABeta adrenergic receptor
antagonist
agonist
Humans
AAlpha adrenergic receptor
antagonist
agonist
Humans
Absorption

Dihydroergocornine absorption in man after oral administration is very rapid when compared to the mixture or most of the components. The time to reach maximum plasma concentration or 0.57 ng-eq/ml is 1.4 hours. It presents an absorption half-life of 0.32 hours. The absorption percentage is of about 25% which corresponds to the registered absorption presented in the ergoloid mixture.8 To know more about the pharmacokinetics please visit Ergoloid mesylate.

Volume of distribution

To know more about the pharmacokinetics please visit Ergoloid mesylate.

Protein binding

To know more about the pharmacokinetics please visit Ergoloid mesylate.

Metabolism

The biotransformation of dihydroergocornine occurs via oxidation and cleavage of the proline in the peptide portion of the molecule as well as by the splitting of the amide bond yielding dihydrolysergic acid amide. Some of the derivate metabolites retain the essential ring structure of the ergot alkaloid.9 To know more about the pharmacokinetics please visit Ergoloid mesylate.

Route of elimination

When orally administered, dihydroergocornine is almost completely eliminated via feces. The urinary secretion accounts only for 2.5% of the administered dose. On the other hand, when administered intravenously, the renal excretion can account for approximately 10% of the administered dose.8 To know more about the pharmacokinetics please visit Ergoloid mesylate.

Half-life

To know more about the pharmacokinetics please visit Ergoloid mesylate.

Clearance

No pharmacokinetic related to the clearance rate was found in current literature.

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Dihydroergocornine effect on fertility was tested in preclinical studies. The reported effect was a decreased weight gain in neonates.10 Overdosing has also been reported to present effects of fall of blood pressure and a decrease in heart rate to 13 beats per minute.4 To know more about the pharmacokinetics please visit Ergoloid mesylate.

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbametapirThe serum concentration of Dihydroergocornine can be increased when it is combined with Abametapir.
AbataceptThe metabolism of Dihydroergocornine can be increased when combined with Abatacept.
AbemaciclibThe metabolism of Abemaciclib can be decreased when combined with Dihydroergocornine.
AcalabrutinibThe metabolism of Acalabrutinib can be decreased when combined with Dihydroergocornine.
AcebutololAcebutolol may increase the vasoconstricting activities of Dihydroergocornine.
Food Interactions
No interactions found.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Dihydroergocornine mesylate42RX8KPW2929261-94-7UOOWRCRLTSXSAV-GSZJWLEYSA-N
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Ergoloid MesylatesDihydroergocornine mesylate (0.333 mg/1) + Dihydro-alpha-ergocryptine mesylate (0.222 mg/1) + Dihydroergocristine mesylate (0.333 mg/1) + Epicriptine mesilate (0.111 mg/1)TabletOralSun Pharmaceutical Industries Limited1991-10-31Not applicableUS flag
Ergoloid MesylatesDihydroergocornine mesylate (0.333 mg/1) + Dihydro-alpha-ergocryptine mesylate (0.333 mg/1) + Dihydroergocristine mesylate (0.333 mg/1)Tablet, orally disintegratingOralIVAX Pharmaceuticals, Inc.1980-11-202008-09-30US flag
Ergoloid MesylatesDihydroergocornine mesylate (0.333 mg/1) + Dihydro-alpha-ergocryptine mesylate (0.222 mg/1) + Dihydroergocristine mesylate (0.333 mg/1) + Epicriptine mesilate (0.111 mg/1)TabletOralCarilion Materials Management1991-10-31Not applicableUS flag
Ergoloid MesylatesDihydroergocornine mesylate (0.333 mg/1) + Dihydro-alpha-ergocryptine mesylate (0.222 mg/1) + Dihydroergocristine mesylate (0.333 mg/1) + Epicriptine mesilate (0.111 mg/1)TabletOralPhysicians Total Care, Inc.1991-10-312012-10-08US flag
Ergoloid MesylatesDihydroergocornine mesylate (0.333 mg/1) + Dihydro-alpha-ergocryptine mesylate (0.222 mg/1) + Dihydroergocristine mesylate (0.333 mg/1) + Epicriptine mesilate (0.111 mg/1)TabletOralFrontida BioPharm, Inc.2017-06-01Not applicableUS flag

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as ergopeptines. These are ergoline derivatives that contain a tripeptide structure attached to the basic ergoline ring in the same location as the amide group of the lysergic acid derivatives.
Kingdom
Organic compounds
Super Class
Alkaloids and derivatives
Class
Ergoline and derivatives
Sub Class
Lysergic acids and derivatives
Direct Parent
Ergopeptines
Alternative Parents
Hybrid peptides / Dipeptides / Lysergamides / Indoloquinolines / Benzoquinolines / Quinoline-3-carboxamides / Pyrroloquinolines / N-acyl-alpha amino acids and derivatives / 3-alkylindoles / Piperidinecarboxamides
show 20 more
Substituents
1,4-diazinane / 3-alkylindole / 3-piperidinecarboxamide / Alkanolamine / Alpha-amino acid or derivatives / Alpha-dipeptide / Amine / Amino acid or derivatives / Aralkylamine / Aromatic heteropolycyclic compound
show 41 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
ergot alkaloid (CHEBI:59909)
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
IK4C1OC8NE
CAS number
25447-65-8
InChI Key
SEALOBQTUQIVGU-QNIJNHAOSA-N
InChI
InChI=1S/C31H41N5O5/c1-16(2)26-28(38)35-11-7-10-24(35)31(40)36(26)29(39)30(41-31,17(3)4)33-27(37)19-12-21-20-8-6-9-22-25(20)18(14-32-22)13-23(21)34(5)15-19/h6,8-9,14,16-17,19,21,23-24,26,32,40H,7,10-13,15H2,1-5H3,(H,33,37)/t19-,21-,23-,24+,26+,30-,31+/m1/s1
IUPAC Name
(2R,4R,7R)-N-[(1S,2S,4R,7S)-2-hydroxy-5,8-dioxo-4,7-bis(propan-2-yl)-3-oxa-6,9-diazatricyclo[7.3.0.0^{2,6}]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(16),9,12,14-tetraene-4-carboxamide
SMILES
[H][C@@]12CCCN1C(=O)[C@H](C(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)(O[C@@]21O)C(C)C

References

General References
  1. HAFKENSCHIEL JH, CRUMPTON CW, MOYER JH, JEFFERS WA, FISHEL HANLEY B, CONLIN HARNED S: The effects of dihydroergocornine on the cerebral circulation of patients with essential hypertension. J Clin Invest. 1950 Apr;29(4):408-11. doi: 10.1172/JCI102273. [Article]
  2. FREIS ED, STANTON JR, et al.: The hemodynamic effects of hypotensive drugs in man; dihydroergocornine. J Clin Invest. 1949 Nov;28(6 Pt 2):1387-1402. doi: 10.1172/JCI102204. [Article]
  3. Bercel NA: TREATMENT OF MIGRAINE-Results with Dihydroergocornine Methanesulfonate (DHO-180) and Other Ergot Derivatives. Calif Med. 1950 Apr;72(4):234-8. [Article]
  4. Hayes DW, Wakim KG, Horton BT, Peters GA: THE EFFECTS OF DIHYDROERGOCORNINE ON THE CIRCULATION IN THE EXTREMITIES OF MAN. J Clin Invest. 1949 Jul;28(4):615-20. doi: 10.1172/JCI102111. [Article]
  5. FLORMAN AL, FISCHER AE, MOLOSHOK RE: An evaluation of the mumps skin-test in pediatric practice. Bull N Y Acad Med. 1949 Jul;25(7):441. [Article]
  6. Muller-Schweinitzer E: Actions of co-dergocrine mesylate and its components at vascular smooth muscle. Naunyn Schmiedebergs Arch Pharmacol. 1982 Feb;318(3):225-33. [Article]
  7. Florey K. (1978). Analytical profiles of drug substances (7th ed.). Academic Press. [ISBN:0-12-260807-0]
  8. Berde B. and Schild H. (1978). Ergot alkaloids and related compounds. Springer-Verlag. [ISBN:978-3-642-66777-0]
  9. Barceloux D. (2008). Medical toxicology of natural substances. Wiley. [ISBN:978-0-470-33447-4]
  10. Preston S. (1917). Endocrinology. Williams & Wilkins Co..
ChemSpider
147720
RxNav
3415
ChEBI
59909
ChEMBL
CHEMBL2365712
ZINC
ZINC000004215648
Wikipedia
Dihydroergocornine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
TabletOral
Tablet, orally disintegratingOral
Tablet
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)187 ºCFlorey K. Analytical profiles of drug substances. 1978.
boiling point (°C)DecomposesFlorey K. Analytical profiles of drug substances. 1978.
logP2.33ChemSrc
Predicted Properties
PropertyValueSource
Water Solubility0.402 mg/mLALOGPS
logP3.1ALOGPS
logP3.06Chemaxon
logS-3.2ALOGPS
pKa (Strongest Acidic)9.71Chemaxon
pKa (Strongest Basic)8.39Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count6Chemaxon
Hydrogen Donor Count3Chemaxon
Polar Surface Area118.21 Å2Chemaxon
Rotatable Bond Count4Chemaxon
Refractivity152.66 m3·mol-1Chemaxon
Polarizability62 Å3Chemaxon
Number of Rings7Chemaxon
Bioavailability1Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-03di-0000090000-c2559da98a65f31cd951
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-03di-0073090000-5083e289ff4f155deb7f
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-03di-0000090000-241a72297b46b4f8779e
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0il1-0139080000-704c0d68d815a4a5bfab
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-05di-0092010000-a6ef07705f39a656e9aa
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0ik9-1195010000-88cc685f7f78c66fa324
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-241.4336497
predicted
DarkChem Lite v0.1.0
[M-H]-226.68616
predicted
DeepCCS 1.0 (2019)
[M+H]+239.2339497
predicted
DarkChem Lite v0.1.0
[M+H]+228.58156
predicted
DeepCCS 1.0 (2019)
[M+Na]+238.8820497
predicted
DarkChem Lite v0.1.0
[M+Na]+234.6534
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein group
Organism
Humans
Pharmacological action
Yes
Actions
Antagonist
Agonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...

Components:
References
  1. Muller-Schweinitzer E: Actions of co-dergocrine mesylate and its components at vascular smooth muscle. Naunyn Schmiedebergs Arch Pharmacol. 1982 Feb;318(3):225-33. [Article]
Kind
Protein group
Organism
Humans
Pharmacological action
Yes
Actions
Antagonist
Agonist
General Function
Receptor signaling protein activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately e...

Components:
References
  1. Muller-Schweinitzer E: Actions of co-dergocrine mesylate and its components at vascular smooth muscle. Naunyn Schmiedebergs Arch Pharmacol. 1982 Feb;318(3):225-33. [Article]
Kind
Protein group
Organism
Humans
Pharmacological action
Yes
Actions
Antagonist
Agonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...

Components:
References
  1. Muller-Schweinitzer E: Actions of co-dergocrine mesylate and its components at vascular smooth muscle. Naunyn Schmiedebergs Arch Pharmacol. 1982 Feb;318(3):225-33. [Article]

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Wooltorton E: Risk of stroke, gangrene from ergot drug interactions. CMAJ. 2003 Apr 15;168(8):1015. [Article]

Drug created at December 03, 2015 16:51 / Updated at January 16, 2021 21:46